Scientific publications

Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha

Jun 1, 1999 | Magazine: Acta Haematologica

Panizo C, Rifón J, Rodríguez-Wilhelmi P, Cuesta B, Rocha E.

Primary plasma cell leukemia (PCL) is a rare form of plasma cell neoplasm with a poor prognosis.

Conventional melphalan-based treatments have been most disappointing. We report the case of a 62-year-old man with a primary form of PCL treated with VAD combination achieving an objective response, and who received high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by interferon-alpha. During the remission time, lasting for 3 years, an infiltration by large granular lymphocytes (LGL) was noted in peripheral blood. However, when the number of LGL declined, a bone marrow relapse was observed.

The treatment for PCL and the possible role of these LGL on tumor cell control after autologous PBSC transplantation are discussed.

CITATION Acta Haematol. 1999;101(4):193-6

Our authors

Navarre headquarters
Madrid headquarters